healthresearch news

A potential novel therapeutic target for non-alcoholic fatty liver disease

By 16th October 2019 October 24th, 2019 No Comments

One of the key comorbidities of type-2-diabetes is non-alcoholic fatty liver disease (NAFLD) – a disease that is increasing worldwide and for which there are no treatment options available today. It can lead to more severe liver damage such as cirrhosis and hepatocellular carcinoma. A group of researchers including the Institute for Diabetes and Cancer at Helmholtz Zentrum München has discovered a potential novel therapeutic target for treating NAFLD: Rab24. The paper is published in Nature Metabolism.

The French members of the team are from C3M at the Université Côte d’Azur.

Read the research paper: Hepatic Rab24 controls blood glucose homeostasis via improving mitochondrial plasticity. Anja Zeigerer et al. Nature Metabolism

Read the press release from the Institute for Diabetes and Cancer at Helmholtz Zentrum München.